Navigation Links
Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice
Date:2/20/2008

Results Demonstrate Potential Future Application of Stem Cells as a

Treatment for Diabetes

Findings published in Nature Biotechnology

SAN DIEGO, Feb. 20 /PRNewswire/ -- Novocell, Inc., a stem cell engineering company, today announced data demonstrating for the first time that human embryonic stem (hES) cells can be turned into pancreatic cells capable of producing insulin in mice. The findings are reported in an article appearing on-line today, in advance of print publication, in the journal Nature Biotechnology. This research provides evidence supporting the potential future use of hES cells to replace insulin-producing pancreatic cells that are destroyed in people with Type 1 diabetes, requiring them to receive regular insulin treatment.

The findings build on two previously reported studies by Novocell (Nature Biotechnology 2005 and 2006), whereby Novocell scientists demonstrated a process that successfully engineers hES cells into specific cells necessary for pancreas formation, and endocrine cells capable of producing insulin and other pancreatic hormones.

In this new work, Novocell has demonstrated that implantation of hES-derived pancreatic cells into mice results in the generation of glucose-responsive insulin producing cells. These cells exhibit properties characteristic of functional adult pancreatic insulin producing cells in the pancreas. Most importantly, these hES-derived cells provide protection in an animal model of diabetes characterized by loss of pancreatic insulin producing cells.

"Our data provide the first compelling evidence that hES cells can serve as a renewable source of functional insulin producing cells for diabetes cell replacement therapies," said Emmanuel Baetge, Ph.D., Chief Scientific Officer of Novocell and senior author of the publication. "It also provides strong evidence that hES cell-derived endoderm cells are able to generate glucose-responsive insulin secreting cells that are functionally similar to adult human beta cells."

Current cellular therapy for diabetes is performed by transplanting donor-derived human islets combined with chronic immunosuppression. While this has been demonstrated to be an effective therapy, the limited availability of donated pancreatic islets and the adverse side effects of long-term immunosuppression make this replacement therapy unsuitable for the general diabetes population.

Together with its stem cell engineering technology for insulin-producing cells, Novocell has also developed a delivery process by which such cells might be delivered to patients without the need for chronic immunosuppression. Novocell's encapsulation technology provides a protective, coating for cells, thus allowing them to be more readily accepted in the body without the chronic use of immunosuppressive drugs. This encapsulation technology has been successfully tested in human clinical trials using human islets isolated from donor organs.

"By developing proprietary processes to successfully generate insulin-producing cells from hES cells in vivo and protecting these cells from immune system rejection, we have created a potential treatment option that could lead to the first widespread application of cell replacement therapy for the treatment of diabetes," said Alan J. Lewis, Ph.D., President and Chief Executive Officer of Novocell. "We look forward to the continued advancement of these technologies that hold such promise for transforming the treatment of diabetes."

About Diabetes

Type 1, or insulin-dependent diabetes occurs when the pancreas ceases to produce insulin due to an autoimmune response that causes the selective destruction of insulin producing cells. People with Type 1 diabetes must take daily insulin and are candidates for pancreatic islet cell transplantation, which provides the potential to treat the disease. The disease is most common in children and young adults, accounting for approximately 10 percent of diabetes cases. The Juvenile Diabetes Research Foundation estimates that more than 1.1 million people suffer from Type 1 diabetes in the United States alone. Additionally, approximately 30 percent of people with Type 2 diabetes require insulin therapy and could potentially benefit from islet cell transplantation

About Novocell

Novocell, Inc. is a stem cell engineering company with research operations in San Diego, California and Athens, Georgia, dedicated to creating, delivering and commercializing cell and drug therapies for diabetes and other chronic diseases. Novocell has three primary technologies: stem cell engineering, cell encapsulation and drug discovery. The Company was founded in 1999 and merged with CyThera, Inc. and BresaGen, Inc. in 2004. For more information, please visit http://www.novocell.com.


'/>"/>
SOURCE Novocell, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
2. Novocell Appoints Orville G. Kolterman, M.D. to Board of Directors
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... and drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the topic ... taking place May 15-18, 2017 in Los Angeles, Calif. Hosted by the Workgroup ...
(Date:4/25/2017)... ... April 25, 2017 , ... L3 Clinical Trials, the Clinical ... is now a certified iMedNet eClinical and Electronic Data Capture software designer for ... research team to build, customize and manage clinical trial data capture and databases ...
(Date:4/25/2017)... ... ... Leaders of Quorum Review IRB and Kinetiq , the ... week’s Association of Clinical Research Professionals (ACRP) 2017 Meeting & Expo with ... are excited to present subject matter expertise on topics that impact the global clinical ...
(Date:4/21/2017)... ... April 21, 2017 , ... Having worked on the ... Formaspace is pleased to introduce it to top lab design architects from around the ... Turk and VP of Industrial Design and Engineering Greg Casey will be at the ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):